Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.6% - Here's Why

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price traded down 5.6% on Wednesday . The company traded as low as $7.04 and last traded at $7.02. 8,745,283 shares changed hands during trading, a decline of 48% from the average session volume of 16,670,846 shares. The stock had previously closed at $7.43.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on RXRX shares. Needham & Company LLC restated a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. KeyCorp cut their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th.

Recursion Pharmaceuticals Price Performance

The stock has a 50-day simple moving average of $6.94 and a 200 day simple moving average of $6.93. The stock has a market capitalization of $2.80 billion, a price-to-earnings ratio of -4.68 and a beta of 0.85. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to analysts' expectations of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business's revenue for the quarter was up 147.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.43) EPS. On average, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of the business's stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total transaction of $87,455.08. Following the transaction, the director now owns 7,066,113 shares in the company, valued at approximately $53,985,103.32. The trade was a 0.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the sale, the chief financial officer now directly owns 1,499,631 shares in the company, valued at $11,487,173.46. The trade was a 0.99 % decrease in their position. The disclosure for this sale can be found here. 15.75% of the stock is owned by company insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in RXRX. Allspring Global Investments Holdings LLC acquired a new position in Recursion Pharmaceuticals during the third quarter worth $25,000. Decker Retirement Planning Inc. bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $26,000. GAMMA Investing LLC boosted its holdings in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after acquiring an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after purchasing an additional 4,091 shares in the last quarter. Finally, KBC Group NV raised its position in Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company's stock valued at $50,000 after purchasing an additional 3,377 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.